ArticleScientific reports2025
An atlas of transcriptomic changes in human immune cells driven by 364 endogenous and gut-microbiota-derived metabolites.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A systematic transcriptomic atlas and predictive framework for metabolite-driven T cell state transitions.iScience · 2026Article
- MaternalBiomedicines · 2026Article
- Decreased degree of adipocyte differentiation in visceral adipose tissue contributes to metabolic dysfunction-associated steatotic liver disease.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Metabolites, particularly those derived from gut microbiota, play crucial roles in modulating immune responses, but the impact of most metabolites on immune cells remains unexplored. To systematically investigate the effect of metabolites on immune cells, we treated peripheral blood mononuclear cells (PBMCs) with 364 endogenous and gut microbiota metabolites and analyzed their impact on the PBMC transcriptome using RNA sequencing (RNA-seq). Clustering analysis revealed three distinct metabolite groups (Cluster 0, 1, 2), each exerting unique immunomodulatory effects. Cluster 1 metabolites, enhanced inflammatory pathways (e.g., cytokine signaling, neutrophil migration) and suppressed ferroptosis, potentially prolonging immune cell activity. In contrast, Cluster 0 metabolites promoted antigen presentation and extracellular matrix repair, while Cluster 2 metabolites upregulated autophagy-related pathways (e.g., GTPase signaling, ubiquitin-protein regulation), suggesting anti-inflammatory and tissue-homeostatic functions. Immune deconvolution highlighted Cluster 1-driven monocyte-to-M0 macrophage differentiation and elevated activated dendritic/mast cells, aligning with pro-inflammatory outcomes. Metabolites in Clusters 0/2 were enriched in the TCA cycle and alanine/aspartate metabolism, whereas Cluster 1 metabolites correlated with beta-alanine and branched-chain amino acid pathways. Gut microbiota analysis identified 23 species overrepresented in Cluster 1, linking dysbiosis to inflammatory metabolite profiles. Together, this high-throughput atlas elucidates how bloodborne metabolites shape PBMC function, offering insights into metabolic-immune crosstalk and potential therapeutic targets for inflammatory and autoimmune disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.